Obesity Surgery

, Volume 18, Issue 2, pp 240–242

Multiple Benign Symmetric Lipomatosis—A DifferentialDiagnosis of Obesity

Is There a Rationale for Fibrate Treatment?
  • Zeitler Heike
  • Ulrich-Merzenich Gudrun
  • Richter Dirk Frank
  • Hans Vetter
  • Peter Walger
Case Report

Abstract

Multiple benign symmetric lipomatosis (MSL) is characterized by a rapid progression of multiple, symmetric nonencapsulated fat masses in face, neck, and extremities. The lipomas are thought to be the result of defective brown adipose tissue (BAT). In up to 90%, MSL is associated with chronic alcohol abuse. Prognosis depends on the concomitant presence of a neuropathy with a mortality of 25.8%. Therapeutic options are limited to alcohol abstinence and surgical interventions. We report here about a 53-year-old MSL patient who increased his body weight by 37 kg over 10 years. Multiple lipectomies were performed but disease progressed. We treated him with fenofibrates (200 mg/day). Disease progression discontinued, and circumferences of abdominal adipose tissue reduced. Fibrates, peroxisome proliferator-activated receptor alpha agonists, are pleiotropic hypolipidemic drugs and might have worked by suppression of protein expressions involved in the architecture of BAT keeping it in a quiescent state.

Keywords

Benign symmetric lipomatosis Triglycerides Fibrates Alcoholism Overweight Surgery Medical treatment Liposuction 

References

  1. 1.
    Enzi G, Busetto L, Ceschin E, et al. Multiple symmetric lipomatosis. Clinical aspects and outcome in a long-term longitudinal study. Int J Obesity 2002;26:253–61.CrossRefGoogle Scholar
  2. 2.
    Vozmediano JF, Armario Hita J. Benign symmetric lipomatosis (Launois–Bensaude syndrome). Int J Dermatol 2005;44:236–7.CrossRefGoogle Scholar
  3. 3.
    Nisoli E, Regianini L, Briscini L, et al. Multiple symmetric lipomatosis may be the consequence of defective noradrenergic modulation of proliferation and differentiation of brown fat cells. J Pathol 2002;198:378–87.PubMedCrossRefGoogle Scholar
  4. 4.
    Kovacs A, Klein C. Madelung Krankheit. Chirurg 1997;68:276–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Pollock M, Nicholson GI, Nukada Cameron S, et al. Neuropathy in multiple symmetric lipomatosis—Madelung’s disease. Brain 1988;11:1157.CrossRefGoogle Scholar
  6. 6.
    Leung NWY, Gaer J, Beggs D, et al. Multiple symmetric lipomatosis (Launois–Benaude –syndrome): effect of oral salbutamol. Clin Endocrinol 1987;7:601.Google Scholar
  7. 7.
    Tong Y, Hara A, Komatsu M, et al. Suppression of muscle associated proteins PPAR alpha in brown adipose tissue. Biochem Biophys Res Commun 2005;336(1):76–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2007

Authors and Affiliations

  • Zeitler Heike
    • 1
    • 3
  • Ulrich-Merzenich Gudrun
    • 1
  • Richter Dirk Frank
    • 2
  • Hans Vetter
    • 3
  • Peter Walger
    • 3
  1. 1.Centre of Extracorporeal Treatment and Lipid Disorders, Medical PoliclinicBonnGermany
  2. 2.Department of Plastic SurgeryDreifaltigkeits Krankenhaus WesselingBonnGermany
  3. 3.Medical PoliclinicUniversity of BonnBonnGermany

Personalised recommendations